Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Position Lessened by Louisiana State Employees Retirement System

Louisiana State Employees Retirement System lowered its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 1.8% during the fourth quarter, HoldingsChannel.com reports. The firm owned 16,800 shares of the specialty pharmaceutical company’s stock after selling 300 shares during the quarter. Louisiana State Employees Retirement System’s holdings in Jazz Pharmaceuticals were worth $2,069,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. CWA Asset Management Group LLC bought a new stake in shares of Jazz Pharmaceuticals in the 3rd quarter valued at approximately $3,197,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Jazz Pharmaceuticals by 135.3% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock worth $19,394,000 after acquiring an additional 100,112 shares in the last quarter. Centre Asset Management LLC acquired a new position in shares of Jazz Pharmaceuticals during the 4th quarter worth $9,335,000. Moloney Securities Asset Management LLC bought a new position in shares of Jazz Pharmaceuticals during the 4th quarter valued at $464,000. Finally, Pacer Advisors Inc. boosted its holdings in Jazz Pharmaceuticals by 15.3% in the third quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock worth $233,892,000 after purchasing an additional 278,465 shares in the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total value of $185,145.00. Following the completion of the transaction, the chief executive officer now owns 425,525 shares of the company’s stock, valued at $52,522,550.75. This represents a 0.35 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last 90 days, insiders sold 5,053 shares of company stock worth $617,442. 4.20% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Stock Down 2.1 %

Shares of JAZZ stock opened at $133.96 on Friday. Jazz Pharmaceuticals plc has a one year low of $99.06 and a one year high of $138.27. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The stock has a fifty day moving average price of $123.47 and a 200 day moving average price of $117.18. The stock has a market cap of $8.10 billion, a P/E ratio of 18.87, a price-to-earnings-growth ratio of 0.92 and a beta of 0.56.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Royal Bank of Canada restated an “outperform” rating and set a $179.00 target price on shares of Jazz Pharmaceuticals in a report on Tuesday, December 10th. Needham & Company LLC restated a “buy” rating and issued a $207.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. Morgan Stanley raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $140.00 to $175.00 in a research report on Thursday, December 12th. Piper Sandler reaffirmed an “overweight” rating and set a $163.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. Finally, TD Cowen dropped their target price on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. One analyst has rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Jazz Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $180.33.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.